2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
K

2020 ASCO Update on Resectable Pancreatic Ductal Adenocarcinoma: Is There a Difference Between Perioperative FOLFIRINOX vs. Gem / nab-P in Efficacy?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Kit Wong
By 2020 ASCO Virtual Direct™ Highlights FEATURING Kit Wong
0 views
December 4, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

23:46
AstraZeneca Oncology

First-line Maintenance Treatment Option in Patients With HRD-Positiv…

Feat. S. Lewin

Featured Video

04:43
Treatment Approach for Advanced Ovarian Cancer

The Role Of Folate Receptor Alpha In Ovarian Cancer

Feat. D. M. O'Malley
GI
11:26
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced HCC: Is Novel Tremelimumab/Durvalumab R…

Feat. K. Wong
06:33
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resectable Pancreatic Ductal Adenocarcinoma: Is …

Feat. K. Wong
07:07
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resectable GE Adenocarcinoma: Does Perioperative…

Feat. K. Wong
06:33
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ Esophageal Adenocarcinoma: Does the Additi…

Feat. K. Wong
07:24
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Stage III CRC: Are Patients with Stage III Colon…

Feat. C. Atreya
06:09
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on BRAFV600E mCRC: How Effective Is FDA Approved 2L…

Feat. C. Atreya
10:08
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ mCRC: Did Trastuzumab Deruxtecan Demonstra…

Feat. C. Atreya
07:34
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Data on Pembro vs. Chemo in MSI-H mCRC: Is There a Clinica…

Feat. C. Atreya